Genfit S.A. (GNFT.PA)
EUR 3.5
(2.04%)
EUR 3.5
(2.04%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 62.25 Million EUR | -11.31% |
| 2022 | 70.19 Million EUR | -2.57% |
| 2021 | 72.04 Million EUR | -60.27% |
| 2020 | 181.34 Million EUR | 1.17% |
| 2019 | 179.24 Million EUR | 7.7% |
| 2018 | 166.43 Million EUR | 3.64% |
| 2017 | 160.58 Million EUR | 3109.83% |
| 2016 | 5 Million EUR | 11.62% |
| 2015 | 4.48 Million EUR | -9.09% |
| 2014 | 4.93 Million EUR | -10.81% |
| 2013 | 5.52 Million EUR | -27.16% |
| 2012 | 7.58 Million EUR | -25.28% |
| 2011 | 10.15 Million EUR | 0.0% |
| 2010 | - EUR | -100.0% |
| 2009 | 6.86 Million EUR | 106.15% |
| 2008 | 3.32 Million EUR | 11.64% |
| 2007 | 2.98 Million EUR | -17.73% |
| 2006 | 3.62 Million EUR | -19.84% |
| 2005 | 4.52 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 55.3 Million EUR | 0.0% |
| 2023 FY | 62.25 Million EUR | -11.31% |
| 2023 Q2 | 67.67 Million EUR | 0.0% |
| 2023 Q4 | 62.25 Million EUR | 0.0% |
| 2022 Q2 | 72.49 Million EUR | 0.0% |
| 2022 FY | 70.19 Million EUR | -2.57% |
| 2022 Q4 | 70.19 Million EUR | 0.0% |
| 2021 Q4 | 72.04 Million EUR | 0.0% |
| 2021 FY | 72.04 Million EUR | -60.27% |
| 2021 Q2 | 68.05 Million EUR | 0.0% |
| 2020 Q4 | 181.34 Million EUR | 0.0% |
| 2020 Q2 | 180.1 Million EUR | 0.0% |
| 2020 FY | 181.34 Million EUR | 1.17% |
| 2019 Q4 | 179.24 Million EUR | 0.0% |
| 2019 Q2 | 177.66 Million EUR | 0.0% |
| 2019 FY | 179.24 Million EUR | 7.7% |
| 2018 Q4 | 166.43 Million EUR | 0.0% |
| 2018 Q2 | 160.69 Million EUR | 0.0% |
| 2018 FY | 166.43 Million EUR | 3.64% |
| 2017 Q4 | 160.58 Million EUR | 0.0% |
| 2017 FY | 160.58 Million EUR | 3109.83% |
| 2017 Q2 | 6.91 Million EUR | 0.0% |
| 2016 Q4 | 5 Million EUR | 0.0% |
| 2016 FY | 5 Million EUR | 11.62% |
| 2016 Q2 | 4.69 Million EUR | 0.0% |
| 2015 Q4 | 4.48 Million EUR | 0.0% |
| 2015 FY | 4.48 Million EUR | -9.09% |
| 2015 Q2 | 1.83 Million EUR | 0.0% |
| 2014 Q4 | 4.93 Million EUR | 0.0% |
| 2014 Q2 | 4.95 Million EUR | 0.0% |
| 2014 FY | 4.93 Million EUR | -10.81% |
| 2013 Q4 | 5.52 Million EUR | 0.0% |
| 2013 Q2 | 6.15 Million EUR | 0.0% |
| 2013 FY | 5.52 Million EUR | -27.16% |
| 2012 Q4 | 7.58 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 7.58 Million EUR | -25.28% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q4 | 10.15 Million EUR | 0.0% |
| 2011 FY | 10.15 Million EUR | 0.0% |
| 2010 FY | - EUR | -100.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2009 FY | 6.86 Million EUR | 106.15% |
| 2009 Q4 | 6.86 Million EUR | 0.0% |
| 2009 Q2 | 1.89 Million EUR | 0.0% |
| 2008 FY | 3.32 Million EUR | 11.64% |
| 2007 FY | 2.98 Million EUR | -17.73% |
| 2006 FY | 3.62 Million EUR | -19.84% |
| 2005 FY | 4.52 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -5554.223% |
| ABIVAX Société Anonyme | 44.69 Million EUR | -39.278% |
| Adocia SA | 4.54 Million EUR | -1271.211% |
| Aelis Farma SA | 2.04 Million EUR | -2939.697% |
| Biophytis S.A. | 3.11 Million EUR | -1901.061% |
| Advicenne S.A. | 15.89 Million EUR | -291.627% |
| genOway Société anonyme | 5.51 Million EUR | -1027.915% |
| IntegraGen SA | 642.28 Thousand EUR | -9592.502% |
| Medesis Pharma S.A. | 1.2 Million EUR | -5087.75% |
| Neovacs S.A. | 650 Thousand EUR | -9477.385% |
| NFL Biosciences SA | 39.2 Thousand EUR | -158696.521% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1328.965% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -3075.64% |
| Sensorion SA | 1.24 Million EUR | -4916.718% |
| Theranexus Société Anonyme | 2.46 Million EUR | -2429.871% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -1497.05% |
| TheraVet SA | 1 Million EUR | -6121.573% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -801.434% |
| argenx SE | 15.35 Million EUR | -305.451% |
| BioSenic S.A. | 15.57 Million EUR | -299.75% |
| Celyad Oncology SA | 902 Thousand EUR | -6801.663% |
| DBV Technologies S.A. | 4.52 Million USD | -1275.453% |
| Galapagos NV | 4.94 Million EUR | -1159.163% |
| GeNeuro SA | 6.49 Million EUR | -858.874% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -17996.802% |
| Innate Pharma S.A. | 30.6 Million EUR | -103.395% |
| Inventiva S.A. | 25.61 Million EUR | -143.024% |
| MaaT Pharma SA | 5.42 Million EUR | -1047.521% |
| MedinCell S.A. | 52.8 Million EUR | -17.903% |
| Nanobiotix S.A. | 41.66 Million EUR | -49.431% |
| Onward Medical N.V. | 16.3 Million EUR | -281.78% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -1704.113% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -75.321% |
| Oxurion NV | 117 Thousand EUR | -53107.692% |
| Pharming Group N.V. | 123.65 Million EUR | 49.657% |
| Poxel S.A. | 40.14 Million EUR | -55.078% |
| GenSight Biologics S.A. | 1.04 Million EUR | -5840.172% |
| Transgene SA | 17 Thousand EUR | -366094.118% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 97.837% |
| Valneva SE | 132.76 Million EUR | 53.111% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |